Diffusion granted US patent for trans biopolar carotenoid molecules

The company also announced that it has received corresponding patents from the South African and the New Zealand Patent Offices. In addition to these newly issued patents, the company has also filed other US patent applications and numerous corresponding foreign and national-stage applications in major international markets.

David Kalergis, Diffusion’s CEO, said: “The issuance of these patents is a vital step in our intellectual property development strategy, furthering our goal of bringing Diffusion Pharmaceutical’s first-in-class therapeutics to market. Our highly unique compounds may one day treat patients with a broad range of disorders involving hypoxia.”